Stoke Therapeutics (STOK) FCF Margin (2022 - 2026)

Stoke Therapeutics' FCF Margin history runs 5 years deep, the most recent figure standing at 977.94% for Q1 2026.

• In Q1 2026, FCF Margin fell 106098.0% year-over-year to 977.94%; the TTM figure through Mar 2026 stood at 459.75% (down 49607.0% YoY), while the FY2025 annual figure was 24.46%, up 26221.0% from the prior year.
• FCF Margin was 977.94% for Q1 2026 at Stoke Therapeutics, up from 2175.32% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 1055.0% in Q1 2022 to a low of 2175.32% in Q4 2025.
• Historically, FCF Margin has averaged 513.66% across 5 years, with a median of 533.4% in 2023.
• Biggest YoY gain for FCF Margin was 66587 bps in 2025; the steepest drop was 207320 bps in 2025.
• A 5-year view of FCF Margin shows it stood at 793.42% in 2022, then rose by 6 bps to 745.11% in 2023, then surged by 86 bps to 102.12% in 2024, then plunged by 2030 bps to 2175.32% in 2025, then soared by 55 bps to 977.94% in 2026.
• The last three FCF Margin figures came in at 977.94% (Q1 2026), 2175.32% (Q4 2025), and 289.25% (Q3 2025), per Business Quant data.